Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67
Enliven Therapeutics Inc ELVN
$54.81
▲ +1.59%
(+$0.86)
🎯 52W High
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$54.10
Prev Close
$53.95
Day Range
$53.10 – $55.82
52W Range
$14.79 – $55.79
Market Cap
$3.92B
Beta
0.52
EPS (TTM)
$-1.66
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-03-12 |
| Shares Out. | 69,820,000 |
| Website | enliventherapeutics.com/ ↗ |
| Phone | 17206478519 |
| Employees | 61 |
| Net Income | -$23.6M |
| Free Cash Flow | -$65.6M |
| Total Assets | $464.9M |
| Total Liabilities | $11.5M |
| Equity | $453.4M |
About Enliven Therapeutics Inc
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics Inc is a publicly traded company under the ticker symbol ELVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)